KemPharm (NASDAQ:KMPH) Lifted to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of KemPharm (NASDAQ:KMPH) from a hold rating to a buy rating in a research report sent to investors on Saturday morning, Zacks.com reports. Zacks Investment Research currently has $1.25 price objective on the specialty pharmaceutical company’s stock.

According to Zacks, “KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product candidates include KP201/APAP, KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303 for the treatment of central nervous system disorders, which are in preclinical trail stage. The Company through its LAT platform technology generate prodrug. KemPharm Inc. is based in CORALVILLE, United States. “

Several other brokerages also recently commented on KMPH. HC Wainwright assumed coverage on KemPharm in a report on Wednesday, June 19th. They set a buy rating and a $3.00 target price on the stock. Oppenheimer dropped their target price on KemPharm from $8.00 to $3.00 and set an outperform rating on the stock in a report on Thursday, May 23rd. Finally, ValuEngine upgraded KemPharm from a sell rating to a hold rating in a report on Thursday, August 1st. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of Buy and an average price target of $2.42.

Shares of NASDAQ:KMPH opened at $0.89 on Friday. The company has a market cap of $25.89 million, a P/E ratio of -0.36 and a beta of 1.39. KemPharm has a one year low of $0.87 and a one year high of $5.47. The business’s 50-day simple moving average is $1.37 and its 200 day simple moving average is $1.71.

KemPharm (NASDAQ:KMPH) last announced its earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.09. Equities research analysts expect that KemPharm will post -1.34 EPS for the current year.

A number of hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. increased its holdings in KemPharm by 134.5% during the 2nd quarter. Vanguard Group Inc. now owns 1,337,571 shares of the specialty pharmaceutical company’s stock worth $2,341,000 after purchasing an additional 767,100 shares during the last quarter. Geode Capital Management LLC increased its holdings in KemPharm by 136.7% during the 4th quarter. Geode Capital Management LLC now owns 171,047 shares of the specialty pharmaceutical company’s stock worth $304,000 after purchasing an additional 98,775 shares during the last quarter. BlackRock Inc. increased its holdings in KemPharm by 21.7% during the 2nd quarter. BlackRock Inc. now owns 106,490 shares of the specialty pharmaceutical company’s stock worth $186,000 after purchasing an additional 19,001 shares during the last quarter. Iowa State Bank increased its holdings in KemPharm by 90.6% during the 2nd quarter. Iowa State Bank now owns 44,171 shares of the specialty pharmaceutical company’s stock worth $77,000 after purchasing an additional 21,000 shares during the last quarter. Finally, Northern Trust Corp increased its holdings in KemPharm by 34.0% during the 4th quarter. Northern Trust Corp now owns 43,445 shares of the specialty pharmaceutical company’s stock worth $78,000 after purchasing an additional 11,014 shares during the last quarter. Institutional investors own 30.11% of the company’s stock.

About KemPharm

KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's product candidate includes KP415 and KP484 for the treatment of attention deficit hyperactivity disorder; and KP879 for the treatment of stimulant use disorder.

Read More: Put Option

Get a free copy of the Zacks research report on KemPharm (KMPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.